Kaléo to pay out more than $12M in false claims case re­gard­ing high-priced ver­sion of cheap opi­oid over­dose an­ti­dote; Uro­Gen gets ready to start PhI­II can­cer tri­al

Vir­ginia phar­ma Kaléo has agreed to pay the Unit­ed States $12.7 mil­lion to re­solve ac­cu­sa­tions that the phar­ma caused the sub­mis­sion of false claims for Evzio, an in­jectable form of nalox­one hy­drochlo­ride in­di­cat­ed for use to re­verse opi­oid over­dose.

Evzio was the high­est-priced ver­sion of nalox­one on the mar­ket, and in­sur­ers had re­quired the sub­mis­sion of pri­or au­tho­riza­tion re­quests be­fore they would ap­prove cov­er­ing Evzio.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.